Symptom burden and quality of life in patients with follicular lymphoma undergoing maintenance treatment with rituximab compared with observation

Therapeutic Advances in Hematology

Volumn 2, Issue 3, 2011, Pages 129-139

  Walker, Mark S ^a   Stepanski, Edward J ^a   Houts, Arthur C ^a   Reyes, Carolina ^b   Satram Hoang, Sacha ^b   Schwartzberg, Lee S ^c  

^a ACORN Research LLC   (United States)

^b GENENTECH INC   (United States)

^c WEST CLINIC   (United States)

Author keywords

follicular lymphoma; maintenance therapy; Rituxan; rituximab; symptoms

Indexed keywords

RITUXIMAB;

ADULT; AGED; ARTICLE; CLINICAL DECISION MAKING; DISEASE COURSE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 84993767789     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620711407675     Document Type: Article

References (36)

1. Boland A. Bagust A. Hockenhull J. Davis H. Chu P. Dickson R. (2009) Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. Health Technol Assess 13(Suppl. 2): 41–48.
2. Buske C. Hoster E. Dreyling M. Hasford J. Unterhalt M. Hiddemann W. (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108: 1504–1508.
3. Cheung M.C. Imrie K.R. Friedlich J. Buckstein R. Lathia N. Mittmann N. (2009) The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity-a preliminary analysis. Psychooncology 18: 554–559.
4. Cnaan A. Laird N.M. Slasor P. (1997) Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 16: 2349–2380.
5. Copay A.G. Subach B.R. Glassman S.D. Polly D.W. Jr Schuler T.C. (2007) Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 7: 541–546.
6. Davis T.A. Grillo-Lopez A.J. White C.A. McLaughlin P. Czuczman M.S. Link B.K. et al (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18: 3135–3143.
7. Dehejia R.H. Wahba S. (1999) Causal effects in nonexperimental studies: reevaluating the evaluation of training programs. J Am Statist Assoc 94: 1053–1062.
8. Fisher R.I. Le Blanc M. Press O.W. Maloney D.G. Unger J.M. Miller T.P. (2005) New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23: 8447–8452.
9. Forstpointner R. Unterhalt M. Dreyling M. Bock H.P. Repp R. Wandt H. et al (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108: 4003–4008.
10. Fortner B. Baldwin S. Schwartzberg L. Houts A.C. (2006) Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. J Pain Symptom Manage 31: 207–214.
11. Friedberg J.W. Taylor M.D. Cerhan J.R. Flowers C.R. Dillon H. Farber C.M. et al (2009) Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 27: 1202–1208.
12. Ghielmini, M.E., Schmitz, S.H., Martinelli, G., Peccatori, F., Hess, U., Fey, M. et al. (2009) Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35 / 98. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology, 29 May–2 June, Orlando, FL.
13. Gine E. Gutierrez-Garcia G. Lopez-Guillermo A. (2010) Current immunochemotherapy strategies in follicular lymphoma. Adv Ther in press.
14. Hainsworth J.D. (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial. Semin Oncol 29(1 Suppl. 2): 25–29.
15. Hochster H. Weller E. Gascoyne R.D. Habermann T.M. Gordon L.I. Ryan T. et al (2009) Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG 1496 Study. J Clin Oncol 27: 1607–1614.
16. Houts A.C. Lipinski D. Olsen J.P. Baldwin S. Hasan M. (2009) Use of the patient care monitor to screen for depression in adult cancer patients interviewed with the structured clinical interview for DSM-IV. Psychooncology in press.
17. Jaeschke R. Singer J. Guyatt G.H. (1989) Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 10: 407–415.
18. Keating G.M. (2010) Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70: 1445–1476.
19. Littell R.C. Pendergast J. Natarajan R. (2000) Modelling covariance structure in the analysis of repeated measures data. Stat Med 19: 1793–1819.
20. Maloney D.G. (2008) What is the role of maintenance rituximab in follicular NHL? Oncology (Williston Park) 22: 20–26. discussion 26, 29, 33–24.
21. Marcus R. Imrie K. Solal-Celigny P. Catalano J.V. Dmoszynska A. Raposo J.C. et al (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26: 4579–4586.
22. National Cancer Institute (2005) SEER cancer statistics review, 1975–2006. Available at: http://www.seer.cancer.gov/csr/1975_2006/index.html.
23. Pettengell R. Donatti C. Hoskin P. Poynton C. Kettle P.J. Hancock B. et al (2008) The impact of follicular lymphoma on health-related quality of life. Ann Oncol 19: 570–576.
24. Revicki D. Hays R.D. Cella D. Sloan J. (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61: 102–109.
25. Ringash J. O'Sullivan B. Bezjak A. Redelmeier D.A. (2007) Interpreting clinically significant changes in patient-reported outcomes. Cancer 110: 196–202.
26. Rosenbaum P.R. Rubin D.B. (1984) Reducing bias in observational studies using subclassification on the propensity score. J Am Statist Assoc 79: 516–524.
27. Salles G. Seymour J.F. Offner F. Lopez-Guillermo A. Belada D. Xerri L. et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377: 42–51.
28. Solal-Celigny P. Cahu X. Cartron G. (2010) Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol 92: 246–254.
29. Stepanski E.J. Walker M.S. Schwartzberg L.S. Blakely L.J. Ong J.C. Houts A.C. (2009) The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer. J Clin Sleep Med 5: 132–136.
30. Tilly H. Zelenetz A. (2008) Treatment of follicular lymphoma: current status. Leuk Lymphoma 49(Suppl. 1): 7–17.
31. van Oers M.H. van Glabbeke M. Giurgea L. Klasa R. Marcus R.E. Wolf M. et al (2010) Rituximab maintenance treatment of relapsed / resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28: 2853–2858.
32. Vidal L. Gafter-Gvili A. Leibovici L. Dreyling M. Ghielmini M. Hsu Schmitz S.F. et al (2009) Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 101: 248–255.
33. Walker M.S. Schwartzberg L.S. Stepanski E.J. Fortner B.V. (2009) A retrospective study of quality of life in a community sample of patients with early stage breast cancer. Breast Cancer Res Treat 115: 415–422.
34. Webster K. Cella D. (1998) Quality of life in patients with low-grade non-Hodgkin's lymphoma. Oncology (Williston Park) 12: 697–714. discussion 714, 717, 721.
35. Witzens-Harig M. Reiz M. Heiss C. Benner A. Hensel M. Neben K. et al (2009) Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial. Ann Hematol 88: 51–57.
36. Witzig T.E. Vukov A.M. Habermann T.M. Geyer S. Kurtin P.J. Friedenberg W.R. et al (2005) Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23: 1103–1108.